Arthritis & Rheumatology最新文献

Longitudinal Changes in Serum Urate Levels from Pre-menopause through Post-menopause: Interrupted Time-Series Analyses. 绝经前至绝经后血清尿酸水平的纵向变化：中断时间序列分析。

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2025-10-02 DOI: 10.1002/art.43406

Shreya Billa,Sho Fukui,Misti L Paudel,Takahiro Suzuki,Ryosuke Imai,Yuntae Kim,Takehiro Nakai,Hiromichi Tamaki,Mitsumasa Kishimoto,Hilde S Ørbo,Sara K Tedeschi,Hyon K Choi,Masato Okada,Daniel H Solomon

{"title":"Longitudinal Changes in Serum Urate Levels from Pre-menopause through Post-menopause: Interrupted Time-Series Analyses.","authors":"Shreya Billa,Sho Fukui,Misti L Paudel,Takahiro Suzuki,Ryosuke Imai,Yuntae Kim,Takehiro Nakai,Hiromichi Tamaki,Mitsumasa Kishimoto,Hilde S Ørbo,Sara K Tedeschi,Hyon K Choi,Masato Okada,Daniel H Solomon","doi":"10.1002/art.43406","DOIUrl":"https://doi.org/10.1002/art.43406","url":null,"abstract":"OBJECTIVESHyperuricemia (HU) and gout are common in post-menopausal women. We aimed to identify the longitudinal changes in serum urate (SU) levels during and after the menopausal transition and its interaction with coexisting SU-modifying conditions.METHODSThis longitudinal study included Japanese women who underwent annual medical examinations from April 2004 to September 2024 and had at least one visit before and after self-reported menopause. Menopausal transition stages were categorized into pre-menopause, peri-menopause (5 years prior to and up to the menopause), and post-menopause. Longitudinal changes in SU and HU (SU ≥6.8 mg/dL or taking medications for gout/HU) were examined by interrupted time-series analyses and evaluated across stratified subgroups.RESULTSWe analyzed 8,169 eligible participants with 93,511 visits over a median follow-up of 13.8 years. SU levels gradually increased during pre-menopause, rose sharply over peri-menopause, and stabilized in post-menopause. Compared to pre-menopause, the mean SU level was 0.41 mg/dL (95% CI: 0.38, 0.43) higher in post-menopause. HU prevalence increased from <1.0% during pre-menopause to 4-5% during post-menopause. Compared to pre-menopause, the associations of a low estimated glomerular filtration rate (<60 mL/min/1.73 m2) and a high body mass index (≥25 kg/m2) with HU were greater in post-menopause; HU was observed in approximately 18% of overweight or obese women at menopause.CONCLUSIONSSU levels rapidly increase during peri-menopause and are already elevated by the time of menopause. Maintaining a normal body weight and preserving kidney function prior to menopause may decrease postmenopausal HU and potentially prevent subsequent gout in women.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"126 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2025-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145209191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is Serum Uric Acid a Mere Bystander or an Active Player in Osteoarthritis Pathogenesis? 血清尿酸在骨关节炎发病过程中是旁观者还是积极参与者？

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2025-10-02 DOI: 10.1002/art.43407

Fangying Wu,Zihan Yang,Yanwen Sheng,Xinyi Xu,Mingchun Yang

引用次数: 0

Clinical Connections 临床联系

IF 10.9 1区医学

Arthritis & Rheumatology Pub Date : 2025-09-29 DOI: 10.1002/art.43389

引用次数: 0

Journal Club 杂志俱乐部

IF 10.9 1区医学

Arthritis & Rheumatology Pub Date : 2025-09-29 DOI: 10.1002/art.43388

引用次数: 0

Sjögren Disease-B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell-Targeted Therapies. Sjögren疾病-B细胞在边缘：从自身免疫到淋巴瘤发生和新的B细胞靶向治疗的兴起。

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2025-09-28 DOI: 10.1002/art.43404

Rachael A Gordon,Sara S McCoy

{"title":"Sjögren Disease-B Cells at the Brink: From Autoimmunity to Lymphomagenesis and the Rise of Novel B Cell-Targeted Therapies.","authors":"Rachael A Gordon,Sara S McCoy","doi":"10.1002/art.43404","DOIUrl":"https://doi.org/10.1002/art.43404","url":null,"abstract":"Sjögren disease (SjD) is a common systemic autoimmune disorder characterized by inflammation of the exocrine glands, resulting in dryness. Patients frequently exhibit extraglandular manifestations affecting various organ systems. To date, there are no FDA-approved disease-modifying therapies for SjD. In this review, we explore the expanding field of SjD endotyping as a tool to enhance patient stratification, prognostication, and clinical decision-making. SjD endotypes driven by heightened B cell activity are linked to increased lymphoma risk. B cells play a central role in SjD pathogenesis by producing autoantibodies, presenting antigens, and releasing pro-inflammatory cytokines. These functions contribute not only to autoimmunity but also to lymphomatous transformation. We illustrate these concepts through the case of a patient with SjD who developed parotid MALT lymphoma after years of recurrent glandular swelling-highlighting a common yet challenging scenario for practicing rheumatologists. Using this case as a framework, we examine the pathobiology of B cells in SjD that drive autoreactivity and lymphomagenesis. Finally, we review emerging B cell-targeted therapies that reflect a broader shift in the SjD treatment landscape from symptomatic management to targeted therapies grounded in disease immunopathology.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"4 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145182688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Influence of Race, Ethnicity and Historical Redlining on Psoriatic Disease Burden and Clinical Outcomes. 种族、民族和历史背景对银屑病负担和临床结局的影响

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2025-09-25 DOI: 10.1002/art.43397

Sharon Dowell,Brittany Banbury,Christopher Jenkins,Emily E Holladay,Fenglong Xie,Jingyi Zhang,Grace C Wright,Jeffrey R Curtis,Gail S Kerr

{"title":"The Influence of Race, Ethnicity and Historical Redlining on Psoriatic Disease Burden and Clinical Outcomes.","authors":"Sharon Dowell,Brittany Banbury,Christopher Jenkins,Emily E Holladay,Fenglong Xie,Jingyi Zhang,Grace C Wright,Jeffrey R Curtis,Gail S Kerr","doi":"10.1002/art.43397","DOIUrl":"https://doi.org/10.1002/art.43397","url":null,"abstract":"OBJECTIVETo evaluate the association of neighborhood deprivation and structural barriers with disease burden in racial and ethnic subsets of patients with psoriatic arthritis (PsA).METHODSPsA patients in the ACR RISE registry with reported race, region, and ≥3 years of follow-up, were evaluated. Demographic factors, disease activity measures, social deprivation, defined by the area deprivation index (ADI) and therapeutic agents were stratified by race. Subgroup analyses were conducted to examine demographic and clinical characteristics across residential areas graded by the Home Owners' Loan Corporation (HOLC), from 'Best' (HOLC 1 - predominantly White residents) to 'Hazardous' (HOLC 4 or redlined - predominantly Black residents) based on investment risk.RESULTSThe cohort included 21,429 predominantly female (57.7%), obese (56.1% BMI>30) PsA patients with median age 55 (12.8) years. High social deprivation was prevalent among Black patients (25.7 % vs. 2.3% Asian, 12.5% White and 17.3% Other), as was High Disease Activity (HDA, 40.2% vs. 25.8% Asian, 29.6% White, and 33.5% Other). Approximately 7% of PsA patients lived in HOLC-graded districts. Smoking, obesity, high social deprivation, federal insurance and HDA were more prevalent in patients in HOLC 4 areas compared to HOLC 1 areas. HOLC 4 patients also had longer median [IQR] periods of HDA (105.0 [0, 690] person-days) and fewer days in remission (1.0 [0, 5457] person-days).CONCLUSIONIn the US, Black PsA patients have prevalent HDA and high social deprivation. Additionally, the enduring effects of structural racism appear to negatively influence PsA disease characteristics of patients living in historically redlined areas.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"16 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145140178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Old techniques still have relevance in personalised predictive medicine. 旧技术在个性化预测医学中仍然具有相关性。

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2025-09-25 DOI: 10.1002/art.43402

Kristina E N Clark,Christopher P Denton

引用次数: 0

Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients with Systemic Lupus Erythematosus and Lupus Nephritis. 胰高血糖素样肽-1受体激动剂的使用和系统性红斑狼疮和狼疮肾炎患者心脏和肾脏不良结局的风险

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2025-09-25 DOI: 10.1002/art.43403

April Jorge,Aakash V Patel,Baijun Zhou,Lingxiao Zhang,Hyon Choi

{"title":"Glucagon-Like Peptide-1 Receptor Agonist Use and the Risk of Adverse Cardiac and Kidney Outcomes Among Patients with Systemic Lupus Erythematosus and Lupus Nephritis.","authors":"April Jorge,Aakash V Patel,Baijun Zhou,Lingxiao Zhang,Hyon Choi","doi":"10.1002/art.43403","DOIUrl":"https://doi.org/10.1002/art.43403","url":null,"abstract":"OBJECTIVEGlucagon-like peptide-1 receptor agonists (GLP-1RA) have cardioprotective and kidney-protective benefits among patients with type 2 diabetes (T2D). We sought to determine whether GLP-1RA use improves cardiovascular (CV) and kidney outcomes among patients with systemic lupus erythematosus (SLE) and lupus nephritis (LN).METHODSWe emulated a pragmatic target trial to evaluate the impact of GLP-1RA vs. comparator hypoglycemic agents, dipeptidyl peptidase 4 inhibitors (DPP4i), on CV and kidney outcomes among patients with SLE and T2D using a large, US multi-center electronic health record database. We used propensity score overlap weighting to emulate randomization between treatment groups. Outcomes included major adverse cardiovascular events, venous thrombosis (VTE), kidney disease progression (eGFR decline ≥ 30% or new-onset end-stage kidney disease), and all-cause mortality. We used Cox regression to compare hazard ratios (HR) based on the weighted populations. In a secondary analysis, we only included patients with LN.RESULTSThere were 910 and 1004 initiators of GLP-1RA and DPP4i, respectively, including 267 and 324 patients with LN, respectively. Baseline covariates were balanced after propensity score overlap weighting. The risks of MACE (HR 0.66 [95% CI 0.48-0.91]), VTE (HR 0.49 [0.24-0.97]), kidney disease progression (HR 0.77 [0.60-0.98]), and all-cause mortality (HR 0.26 [CI 0.10-0.68]) were lower with GLP-1RA vs. DPP4i use. GLP-1RA use was similarly associated with lower risks of MACE and kidney disease progression among patients with LN.CONCLUSIONWe found lower risks of adverse CV and kidney outcomes and mortality with GLP-1RA use compared with DPP4i use among patients with lupus and T2D.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"86 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2025-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145133910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Polyamine Takes the Fast Track to Attack Crystal-Induced Inflammation. 一种多胺能快速治疗晶体引起的炎症。

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2025-09-22 DOI: 10.1002/art.43405

Monica Guma,Robert Terkeltaub

引用次数: 0

Long-term remission with ustekinumab in a patient with PAPA syndrome suggests the importance of IL-12/IL-23 cytokines in PSTPIP1-associated inflammatory diseases. ustekinumab治疗PAPA综合征患者的长期缓解提示IL-12/IL-23细胞因子在pstpip1相关炎症性疾病中的重要性。

IF 13.3 1区医学

Arthritis & Rheumatology Pub Date : 2025-09-22 DOI: 10.1002/art.43399

Nico Wittmann,Dominik Nell,Magdalena Mohs,Marie C Grude,Neha Mishra,Almut Meyer-Bahlburg,Lukas Bossaller

引用次数: 0